The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FORWARD II: A phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FRα)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer.
 
David M. O'Malley
No Relationships to Disclose
 
Lainie P. Martin
No Relationships to Disclose
 
Kathleen N. Moore
No Relationships to Disclose
 
Dale L. Nepert
No Relationships to Disclose
 
Rodrigo Ruiz-Soto
No Relationships to Disclose
 
Ignace Vergote
No Relationships to Disclose